- Home
- GDRX
GDRX
GoodRx Holdings Inc.
as 06-30-2025 11:31am EST
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | SANTA MONICA |
| Market Cap: | N/A | IPO Year: | 2020 |
| Target Price: | $6.33 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.67 - $9.26 | Next Earning Date: | 08-07-2025 |
| Revenue: | $797,414,000 | Revenue Growth: | 4.35% |
| Revenue Growth (this year): | 5.54% | Revenue Growth (next year): | 5.34% |
Stock Insider Trading Activity of GoodRx Holdings Inc. (GDRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Spectrum Equity VII, L.P. | GDRX | 10% Owner | Jun 5 '25 | Sell | $4.09 | 10,677 | $43,706.30 | 0 |
Latest GoodRx Holdings Inc. News
GDRX Breaking Stock News: Dive into GDRX Ticker-Specific Updates for Smart Investing
Insider Monkey
4 days ago
GoodRx (GDRX) Unveils Lifecycle to Enhance Engineering Methodologies
Insider Monkey
7 days ago
KeyBanc Maintains Overweight Rating on GoodRx (GDRX)
Insider Monkey
16 days ago
GoodRx (GDRX) Launches a New Subscription Service for Erectile Dysfunction Treatment
Simply Wall St.
19 days ago
High Growth Tech Stocks In The US To Watch This June 2025
Zacks
20 days ago
DOCS Boosts Client Retention via Workflow Integration and AI Tools
StockStory
20 days ago
GDRX Q1 Earnings Call: Management Focuses on Pharmacy Partnerships and Marketplace Evolution
StockStory
20 days ago
3 Small-Cap Stocks Facing Headwinds
Business Wire
21 days ago
GoodRx Launches New Erectile Dysfunction Subscription Service to Simplify Access and Eliminate Treatment Barriers
Compare GDRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GDRX GoodRx Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.